Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 3/20 | 0.53 |
| ▸ | DRD4 | P21917 | 11/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5150493 | 1.00 | PDK1 (0.53) | PDK1DRD4EPHA2KDREPHB4 | |
| SCHEMBL23107088 | 0.85 | PDK1 (0.50) | PDK1DRD4HRH3DRD2 | |
| SCHEMBL295932 | 0.83 | PDK1 (0.49) | PDK1DRD4HRH3DRD2 | |
| SCHEMBL5368215 | 0.83 | PDK1 (0.49) | PDK1DRD4HRH3 | |
| SCHEMBL5148568 | 0.83 | PDK1 (0.49) | PDK1DRD4HRH3DRD2 | |
| Hydrochloric Acid SCHEMBL5147633 | 0.82 | PDK1 (0.48) | PDK1DRD4HRH3DRD2 | |
| Hydrochloric Acid SCHEMBL5363720 | 0.82 | PDK1 (0.48) | PDK1DRD4HRH3DRD2 | |
| SCHEMBL10263231 | 0.81 | PDK1 (0.53) | PDK1DRD4HRH3DRD2 | |
| SCHEMBL6064721 | 0.81 | KDM4E (0.42) | PDK1DRD4EPHA2KDREPHB4 | |
| SCHEMBL24037258 | 0.81 | PDK1 (0.53) | PDK1DRD4HRH3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071316-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | Kineta Immuno-Oncology LLC | 2020-03-05 | — | — | US | disclosed |
| WO-2020033782-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-1\" PATHWAY AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2020-02-13 | — | — | WO | disclosed |
| EP-1147104-B1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-1709965-A2 | Methods of treating cytokine mediate diseases | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2006-10-11 | — | — | EP | disclosed |
| US-6916814-B2 | Methods of treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071316-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | RARB, RARG, RARA | PDK1 2741/4885DRD4 3534/4885EPHA2 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.